# Merck Sharp & Dohme LLC: Phase 3 study closed enrollment, 6033 enrolled (Papillomavirus Infections)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) |
| NCT ID | NCT04199689 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Papillomavirus Infections |
| Intervention types | biological, other |
| Target enrollment | 6033 |
| Site countries | United States, Belgium, Brazil, Colombia, Czechia, France, Germany, Israel, Italy, Japan, Mexico, Peru |
| Posted | 2019-12-16 |
| Planned start | 2020-02-27 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-20 |
| Last update posted | 2026-10-20 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 6033 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04199689). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.